Globus Medical (NYSE:GMED) Stock Rating Lowered by Wall Street Zen

Globus Medical (NYSE:GMED) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

Several other equities analysts have also issued reports on the company. BMO Capital Markets lowered Globus Medical from an “outperform” rating to a “market perform” rating and cut their price target for the company from $94.00 to $78.00 in a research note on Friday. UBS Group started coverage on Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective for the company. Needham & Company LLC dropped their price objective on Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a report on Friday. Wells Fargo & Company upped their target price on shares of Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $96.92.

Globus Medical Trading Down 0.5%

Shares of GMED stock opened at $70.67 on Friday. Globus Medical has a 1 year low of $70.39 and a 1 year high of $101.40. The firm’s 50 day moving average is $77.20 and its 200-day moving average is $83.18. The firm has a market capitalization of $9.49 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 1.14 and a beta of 0.98.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The business had revenue of $763.72 million for the quarter, compared to analysts’ expectations of $792.39 million. During the same period in the prior year, the firm earned $1.18 earnings per share. Globus Medical’s revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts forecast that Globus Medical will post 4.99 earnings per share for the current fiscal year.

Insider Transactions at Globus Medical

In other news, Director James R. Tobin sold 30,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. This represents a 66.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ann Rhoads sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director owned 35,384 shares in the company, valued at $3,007,640. This represents a 12.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 60,000 shares of company stock worth $4,838,400. 18.38% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Globus Medical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Elevation Wealth Partners LLC raised its holdings in Globus Medical by 2,178.6% during the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after acquiring an additional 305 shares in the last quarter. Continuum Advisory LLC bought a new position in Globus Medical in the second quarter valued at approximately $25,000. Root Financial Partners LLC bought a new position in Globus Medical in the third quarter valued at approximately $29,000. Heritage Family Offices LLP acquired a new position in shares of Globus Medical during the 3rd quarter worth approximately $31,000. Finally, Jacobi Capital Management LLC bought a new stake in shares of Globus Medical during the 3rd quarter worth approximately $40,000. 95.16% of the stock is owned by institutional investors.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

About Globus Medical